Wide Ranks

MRNS

Marinus Pharmaceuticals, Inc.

0.3248

Top Statistics
Market Cap 17 M Forward PE -0.4331 Revenue Growth 32.50 %
Current Ratio 2.28 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.3900 Enterprise / Revenue 1.66 Price To Sales Trailing12 Months 0.5923
Profitability
Profit Margins 0.00 % Operating Margins -375.94 %
Balance Sheet
Total Cash 64 M Total Cash Per Share 1.17 Total Debt 95 M
Total Debt To Equity Current Ratio 2.28 Book Value Per Share 0.3070
All Measures
Short Ratio 109.00 % Message Board Id finmb_7606380 Shares Short Prior Month 3 M
Return On Equity -29.87 City Radnor Uuid fa2311e7-a277-341e-95c3-c3f56aa168dd
Previous Close 0.3218 First Trade Date Epoch Utc 1 B Book Value 0.3070
Beta 1.26 Total Debt 95 M Volume 589470
Price To Book 1.06 Last Split Date 1 B Fifty Two Week Low 0.2600
Total Cash Per Share 1.17 Total Revenue 30 M Shares Short Previous Month Date 1 B
Target Median Price 1.50 Audit Risk 7 Max Age 86400
Recommendation Mean 2.40 Sand P52 Week Change 0.3133 Operating Margins -375.94 %
Target Mean Price 1.47 Net Income To Common -149238000 Short Percent Of Float 0.1032
Implied Shares Outstanding 55 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 999960 Average Volume10days 999960 Total Cash 64 M
Next Fiscal Year End 1 B Revenue Per Share 0.5390 Held Percent Insiders 0.1094
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 6 Regular Market Previous Close 0.3218 Target Low Price 0.3000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.04 Open 0.3218
Free Cashflow -66132124 State PA Dividend Yield 0.00 %
Return On Assets -0.5775 Time Zone Short Name EST Board Risk 8
Trailing Eps -2.47 Day Low 0.3108 Address1 5 Radnor Corporate Center
Shares Outstanding 55 M Compensation Risk 8 Price Hint 4
Target High Price 3.00 Website https://marinuspharma.com 52 Week Change -0.9517
Average Volume 2 M Forward Eps -0.7000 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 189.90 % Last Split Factor 1:4
Regular Market Day High 0.3250 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 11.26 Day High 0.3250 Shares Short 5 M
Regular Market Open 0.3218 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1.66 Revenue Growth 32.50 % Shares Percent Shares Out 0.1028
Operating Cashflow -120467000 Currency USD Time Zone Full Name America/New_York
Market Cap 17 M Is_nasdaq_100 False Zip 19087
Quote Type EQUITY Industry Biotechnology Long Name Marinus Pharmaceuticals, Inc.
Overall Risk 7 Regular Market Day Low 0.3108 Held Percent Institutions 0.8304
Current Price 0.3248 Address2 Suite 500 100 Matsonford Road Enterprise To Ebitda -0.3900
Financial Currency USD Current Ratio 2.28 Gross Margins -221.93 %
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 37 M Two Hundred Day Average 2.87 Governance Epoch Date 1 B
Enterprise Value 50 M Price To Sales Trailing12 Months 0.5923 Forward PE -0.4331
Regular Market Volume 589470 Ebitda -128656000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.

It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.

It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex.

Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co.

, Ltd.

Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.